Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results
In eTNBC and mTNBC, PD-L1-positive status was associated with more favourable long-term outcomes, possibly due to tumour-intrinsic characteristics and/or the host immune response. The high proportion with de novo mTNBC may suggest enrolment bias and/or geographic variations in stage at diagnosis.
Authors
- Elona Juozaitytė (ORCID: https://orcid.org/0000-0001-6695-7786)
- Alişan Zirtiloğlu (ORCID: https://orcid.org/0000-0002-3319-3983)
- Regula Deurloo
- J. Eglītis
- Götz Hartleben
- Saghir Ns
- Saad Akhtar (ORCID: https://orcid.org/0000-0002-4294-0944)
- Lazar Popović (ORCID: https://orcid.org/0000-0002-3278-6875)
- Corrado D’Arrigo
- Iman Estaytieh
- Dinesh C. Doval
- Sitki Tuzlali
- João Mouta
- Rebecca Dent
- Enya Weber
- Paula Toro
- Carlos A. Castaneda
Institutions
- Roche (Switzerland) (CH)
- Lithuanian University of Health Sciences (LT)
- University of Tuzla (BA)
- University of Novi Sad (RS)
- Kingston Maurward College (GB)
- King Faisal Specialist Hospital & Research Centre (SA)
- Rajiv Gandhi Cancer Institute and Research Centre (IN)
- Roche Pharma AG (Germany) (DE)
- American University of Beirut Medical Center (LB)
- Oncology Institute of Vojvodina (RS)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Duke-NUS Medical School (SG)
- Hospital Universitário de Brasília (BR)
- National Cancer Centre Singapore (SG)
- Roche (Portugal) (PT)
- Roche (Lebanon) (LB)
- Roth and Rau (Germany) (DE)
- University of Latvia (LV)
Publication Details
- Journal
- The Breast
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1016/j.breast.2026.104720
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- F. Hoffmann-La Roche
- Eisai
- Genentech
- Daiichi Sankyo Europe